Marginal zone lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance

Author(s): Lasica, M; Anderson, MA; Boussioutas, A; Gregory, GP; Hamad, N; Manos, K; McKelvie, P; Ng, M; Campbell, B; Palfreyman, E; Salvaris, R; Weinkove, R; Wight, J; Opat, S; Tam, C;
Details: Publication Year 2024-06,Volume 54,Issue #6,Page 1017-1030
Journal Title: Internal Medicine Journal
Abstract: Marginal zone lymphomas (MZLs) are a rare, indolent group of non-Hodgkin lymphomas with different diagnostic, genetic and clinical features and therapeutic implications. The most common is extranodal MZL of mucosa-associated lymphoid tissue, followed by splenic MZL and nodal MZL. Patients with MZL generally have good outcomes with long survival rates but frequently have a relapsing/remitting course requiring several lines of therapy. The heterogeneous presentation and relapsing course present the clinician with several diagnostic and therapeutic challenges. This position statement presents evidence-based recommendations in the setting of Australia and New Zealand.
Publisher: Wiley
Keywords: Humans; *Lymphoma, B-Cell, Marginal Zone/diagnosis/therapy; Australia; New Zealand; Consensus; Australasian Lymphoma Alliance; marginal zone lymphoma; practice statement; treatment
Research Division(s): Blood Cells And Blood Cancer
PubMed ID: 38881453
Publisher's Version: https://doi.org/10.1111/imj.16390
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2024-06-24 11:29:56

Last Modified: 2024-06-24 11:34:39